We demonstrated that several members of the HSP90 (HSP90B1, HSP90B2P) and PI3K family (AKT2) were linked to shorter OS, DFS, and adverse clinical features in ACC including advanced stage and metastasis, supporting the use of the HSP90 and PI3K inhibitors in combination. This evidence concerns the gene HSP90AB1 and adrenal cortex carcinoma.